Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 8/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 4/20 | 0.34 |
| ▸ | PRKCB | P05771 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009014 | 0.84 | PIK3CD (0.51) | PIK3CDHRH3GRM5HSP90AA1ALDH1A1 | |
| SCHEMBL26241331 | 0.83 | PIK3CD (0.51) | PIK3CDLMNAALOX15TSHRHSD17B10 | |
| SCHEMBL22055016 | 0.78 | PIK3CD (0.51) | PIK3CDGRM5HSP90AA1ALDH1A1MAPT | |
| SCHEMBL20009042 | 0.74 | PIK3CD (0.50) | PIK3CDHRH3GRM5HSP90AA1ALDH1A1 | |
| SCHEMBL20009023 | 0.73 | PIK3CD (0.55) | PIK3CDGHSRALDH1A1PKM | |
| SCHEMBL20008988 | 0.73 | PIK3CD (0.55) | PIK3CDGHSRALDH1A1PKM | |
| SCHEMBL20009029 | 0.73 | PIK3CD (0.55) | PIK3CDGHSRALDH1A1PKM | |
| SCHEMBL19710931 | 0.73 | PIK3CD (0.70) | PIK3CDLMNAALOX15TSHRHSD17B10 | |
| SCHEMBL26243687 | 0.73 | PRKCB (0.42) | LMNAALOX15TSHRHSD17B10HRH3 | |
| SCHEMBL20009111 | 0.72 | PIK3CD (0.38) | PIK3CDHRH3ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | PIK3CD 3161/4885LMNA 1055/4885ALOX15 4460/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | PIK3CD 3161/4885LMNA 1055/4885ALOX15 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.